About Orphalan
Orphalan is a company based in Paris (France) founded in 2011. Orphalan has completed 1 acquisition, including ORPHELIA Pharma. Orphalan offers products and services including Cuvrior and iWilson’s Disease Registry. Orphalan operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Orphalan Sa
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orphalan
Orphalan offers a comprehensive portfolio of products and services, including Cuvrior and iWilson’s Disease Registry.
Medication for treating Wilson disease in patients.
Database for tracking Wilson disease treatment effectiveness.
People of Orphalan
Unlock access to complete
Funding Insights of Orphalan
Detailed funding history for Orphalan
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orphalan
Orphalan has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ORPHELIA Pharma.
Investment portfolio details for Orphalan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for pediatric neurology, oncology, and hematology are developed.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Orphalan
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Orphalan
Detailed financials for Orphalan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orphalan Comparisons
Peer comparison for Orphalan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orphalan
Orphalan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
|
| Locked | Locked | Locked |
Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema.
|
Detailed competitors of Orphalan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orphalan
Complete news archive for Orphalan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orphalan
Orphalan was founded in 2011.
Orphalan is headquartered in Paris, France.
Naseem Amin is the current CEO of Orphalan.
Orphalan was founded in 2011 in Paris, France, to address needs in the rare disease sector. Operations focus on the development of specialized therapies within the pharmaceutical and healthcare industries. Access to these innovative treatments is ensured for patients worldwide, particularly those with limited options. The company is led by CEO Naseem Amin, with efforts centered on bridging gaps in rare disease care through targeted distribution and support services.
Orphalan's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
Orphalan offers Cuvrior and iWilson’s Disease Registry.
Orphalan has made 1 acquisition, including ORPHELIA Pharma.